Fisetin vs FOXO4-DRI
A side-by-side research comparison of Fisetin and FOXO4-DRI across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Fisetin | FOXO4-DRI |
|---|---|---|
| Full name | Fisetin (Senolytic Flavonoid) | FOXO4-D-Retro-Inverso Peptide (Senolytic) |
| Category | Anti-Aging | Anti-Aging |
| Status | Dietary compound (research ongoing) | Research compound |
| Mechanism | Acts as a senolytic by tipping senescent cells toward apoptosis (programmed death) while sparing healthy cells. Also has antioxidant and anti-inflammatory activity. | Competitively disrupts FOXO4 sequestration of p53 in senescent cells, releasing p53 to trigger intrinsic apoptosis selectively in cells relying on this survival mechanism. |
| Molecular weight | 286.24 Da | ~4,500 Da |
| Half-life | Short; poor baseline absorption (often taken with fat) | 12-24 hours (D-amino acid stability) |
| Bioavailability | Low oral; improved with lipids/liposomal forms | Moderate (SubQ) |
| Typical dose | ~20 mg/kg on hit days (protocol-dependent) | 5-10 mg/kg (animal studies) |
| Frequency | Intermittent "hit and run" courses | 3x per week for 3 weeks |
| Route | Oral | Subcutaneous |
Fisetin reported benefits
- Senolytic (clears senescent cells)
- Antioxidant and anti-inflammatory
- Studied for healthspan extension
- Neuroprotective signals in research
FOXO4-DRI reported benefits
- Selective senescent cell elimination
- Potential aging reversal
- Improved tissue function
- Reduced inflammatory burden
- Hair regrowth (mice)
Related comparisons
Research and educational reference only. Not medical advice.